Homehealthcare News

    Cadila receives USFDA nod to market generic Droxidopa capsules

    Cadila receives USFDA nod to market generic Droxidopa capsules

    Cadila receives USFDA nod to market generic Droxidopa capsules
    Profile image

    By CNBCTV18.com  IST (Published)

    Mini

    Drug major Zydus Cadila has received tentative approval from the US health regulator to market generic Droxidopa capsules.

    Drug major Zydus Cadila has received tentative approval from the US health regulator to market generic Droxidopa capsules.
    “The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Droxidopa capsules in the strengths of 100 mg, 200 mg, and 300 mg,” the company said in a regulatory filing on Saturday.
    Droxidopa is used to treat symptoms of low blood pressure when standing, caused by a certain medical condition, it added.
    The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad, the company said.
    The group now has 290 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of the filing process.
    Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
    arrow down

      Most Read

      Market Movers

      View All
      CompanyPriceChng%Chng